Pfizer Reports Topline Results From Phase 3 TALAPRO-3 Study Of TALZENNA In Combination With XTANDI Improves Radiographic Progression-Free Survival In Metastatic Prostate Cancer

Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA in combination with XTANDI for metastatic hormone-sensitive prostate cancer. The study met its primary endpoint, showing a statistically significant improvement in radiographic progression-free survival (rPFS), with a hazard ratio of 0.63. The results indicate consistent efficacy in patients with both BRCA and non-BRCA HRR gene alterations, and there is a strong trend toward improved overall survival. Pfizer plans to discuss these findings with global health authorities to potentially expand the indication for TALZENNA.